GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in insulin secretion and a lowering of glucagon secretion; in addition, they lower body weight and systolic blood pressure and increase heart rate. Using a new monoclonal antibody for immunohistochemistry, we detected GLP-1 receptor (GLP-1R) in important target organs in humans and monkeys. In the pancreas, GLP-1R was predominantly localized in β-cells with a markedly weaker expression in acinar cells. Pancreatic ductal epithelial cells did not express GLP-1R. In the kidney and lung, GLP-1R was exclusively expressed in smooth muscle cells in the walls of arteries and arterioles. In the heart, GLP-1R was localized in myocytes of the sinoatrial node. In the gastrointestinal tract, the highest GLP-1R expression was seen in the Brunner's gland in the duodenum, with lower level expression in parietal cells and smooth muscle cells in the muscularis externa in the stomach and in myenteric plexus neurons throughout the gut. No GLP-1R was seen in primate liver and thyroid. GLP-1R expression seen with immunohistochemistry was confirmed by functional expression using in situ ligand binding with 125I-GLP-1. In conclusion, these results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLP-1R.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R is present beyond the confines of the pancreas and extends to a multitude of organs and tissues throughout the body. Its extensive distribution and involvement in diverse physiological processes emphasize the important role of GLP-1R beyond the regulation of glucose metabolism.38–40”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [38]
In the citing paper
“Nevertheless, studies using antibodies that appear to be specific for this receptor are consistent with results from gene expression studies, demonstrating staining for the GLP-1 receptor in human and primate kidney in juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“The major site of expression appears to be in the renin-expressing juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“despite only modest expression of the GLP-1 receptor in the kidney”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [74]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“This strain of mice is on a C57BL background and is derivedfromthepreviouslydescribedGLP-1Rknockoutstrain(20) custom bred by Novo Nordisk A/S at Taconic.”
MethodBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“In situ ligand binding for functional GLP-1R localization was performed as described previously, apart from the use of (125)IGLP-1 (7–36) (NEX3080; PerkinElmer) instead of (125)I-exendin (9–39) (21, 22).”
MethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“GLP-1 has been shown to inhibit gastric acid secretion and gastric motility (36), and these effects fit well with our GLP-1R IHC findings.”
ResultTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 5×
“1284 Pyke et al Immunolocalization of GLP-1R Endocrinology, April 2014, 155(4):1280–1290”
BackgroundInfluentialSelf-citationCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“The low-level GLP-1R expression in acinar cells reported in this study corresponds well with previous reports using ISLB on normal human pancreas (8, 25).”
BackgroundResultInfluentialWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Cited by
Items 201–300 of 880
Renoprotective Effects of DPP-4 Inhibitors
Kawanami, D., Takashi, Y., Takahashi, H., Motonaga, R., & Tanabe, M. (2021) · Antioxidants · doi:10.3390/antiox10020246 · Cited by 66
“Investigations by use of monoclonal antibodies against GLP-1R have revealed that it expressed mainly in the vasculature of the kidney [15,16,18].”
BackgroundHuman Beta Cell Regenerative Drug Therapy for Diabetes: Past Achievements and Future Challenges
Wang, P., Karaköse, E., Choleva, L., Kumar, K., DeVita, R. J., García-Ocaña, A., & Stewart, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.671946 · Cited by 61
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0507 · Cited by 54
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
“Here, a dense network of GLP-1 receptors can be demonstrated in the myenteric and the submucous intestinal ganglia (340).”
Nestor, J. J., Parkes, D., Feigh, M., Suschak, J. J., & Harris, M. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-10577-2 · Cited by 53
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes
Petri, K. C. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13358 · Cited by 53
“While the clinical significance of the increase remains unknown, the presence of GLP-1 receptors on the sinoatrial node may indicate a direct chronotropic effect.(27) In the present analysis, there was no evidence of an exposure-pulse rate relationship at”
BackgroundDhir, G., & Cusi, K. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000554 · Cited by 53
Emerging diabetes therapies: Bringing back the β-cells
Basile, G., Qadir, M. M. F., Mauvais‐Jarvis, F., Vetere, A., Shoba, V. M., Modell, A. E., Pastori, R. L., Russ, H. A., Wagner, B. K., & Domínguez‐Bendala, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101477 · Cited by 63
Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non‐Alcoholic Steatohepatitis
Ipsen, D. H., Rolin, B., Rakipovski, G., Skovsted, G. F., Madsen, A., Kolstrup, S. H., Schou‐Pedersen, A. M. V., Skat‐Rørdam, J., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13082 · Cited by 59
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
“When the human 3F52 antibody was utilized in monkey and human tissues, Pyke et al.118 reported the detection of GLP-1R signal in smooth muscle cells in the walls of arteries and arterioles.”
MethodObesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches
Althoff, M. D., Gaietto, K. M., Holguín, F., & Forno, E. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202406-1166so · Cited by 67
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets
Tudurí, E., López, M., Diéguez, C., Nadal, Á., & Nogueiras, R. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.004 · Cited by 56
“It is not only highly expressed in b cells of multiple species, including humans [22,23], but is also found in many other tissues, such as kidney, lung, brain, muscle, and the GI tract [23,24].”
BackgroundEid, L. E., Reynolds, C. A., Tomás, A., & Jones, B. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106411 · Cited by 57
Faber, R., Zander, M., Pena, A., Michelsen, M. M., Mygind, N. D., & Prescott, E. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0206-3 · Cited by 51
“GLP-1 receptors are found throughout the gastrointestinal tract as well as in cardiomyocytes, endothelium and the sinoatrial node [9,10].”
BackgroundYang, M., Wang, J., Wu, S., Yuan, L., Zhao, X., Liu, C., Xie, J., Jia, Y., Lai, Y., Zhao, A. Z., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.28 · Cited by 50
“Therefore, it is possible that once secreted in a paracrine fashion (local to the site of release in the small intestine), GLP-1 activates GLP-1Rs expressed in mucosal cells of the upper gastrointestinal tract through vagal afferent neurons to regulate glucose production.(14) However, whether intestinal GLP-1 has any…”
BackgroundZhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0148827 · Cited by 50
Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0007 · Cited by 48
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“Although a study conducted in ob/ob mice suggested that exendin-4 treatment might reverse hepatic steatosis [148], a recent study did not support the existence of GLP-1R in liver cells of primates including monkeys and humans [59].”
BackgroundMethodResultInfluentialJensen, J. K., Binderup, T., Grandjean, C. E., Bentsen, S., Ripa, R. S., & Kjaer, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.032 · Cited by 49
Antidiabetic Medication and Asthma Attacks
Lee, B., Man, K. K. C., Wong, E., Tan, T., Sheikh, A., & Bloom, C. I. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.5982 · Cited by 59
GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder
Jerlhag, E. (2025) · Endocrinology · doi:10.1210/endocr/bqaf028 · Cited by 64
Gaspari, T., Brdar, M., Lee, H. W., Spizzo, I., Hu, Y., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115605000 · Cited by 49
GLP-1 Receptor: A New Target for Sepsis
Yang, F., Zeng, F., Luo, X., Lei, Y., Li, J., Lu, S., Huang, X., Lan, Y., & Liu, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706908 · Cited by 48
Antidiabetic Agents and Endothelial Dysfunction – Beyond Glucose Control
Eriksson, L., & Nyström, T. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12402 · Cited by 52
Li, J., Zheng, J., Wang, S., Lau, H. K., Fathi, A., & Wang, Q. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00015 · Cited by 47
“GLP-1R has been identified in the vascular smooth muscle cells (VSMCs) of both rodents and humans (Pyke et al., 2014; Richards et al., 2014).”
BackgroundInfluentialModulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
Ang, R., Mastitskaya, S., Hosford, P. S., Basalay, M., Specterman, M., Aziz, Q., Li, Y., Orini, M., Taggart, P., Lambiase, P. D., et al. (2018) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.118.006740 · Cited by 47
Li, Y., Glotfelty, E. J., Karlsson, T., Fortuno, L. V., Harvey, B. K., & Greig, N. H. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15521 · Cited by 47
“Whereas, the GLP- 1 receptor (GLP- 1R) resides ubiquitously in the pancreas, it is also expressed in other tissues (Pyke et al., 2014), including the brain where its activation produces cell- typespecific pleiotropic effects (Rowlands et al., 2018).”
BackgroundFarokhnia, M., Browning, B. D., Crozier, M. E., Sun, H., Akhlaghi, F., & Leggio, L. (2022) · Addiction Biology · doi:10.1111/adb.13211 · Cited by 46
The Role of Mitochondria in Diabetic Kidney Disease and Potential Therapeutic Targets
Takasu, M., Kishi, S., Nagasu, H., Kidokoro, K., Brooks, C. R., & Kashihara, N. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.10.035 · Cited by 58
The role of gut endocrine cells in control of metabolism and appetite
Parker, H. E., Gribble, F. M., & Reimann, F. (2014) · Experimental Physiology · doi:10.1113/expphysiol.2014.079764 · Cited by 56
“Numerous studies have reported additional cardiovascular, renal and neurological1 effects of GLP-1 agonists, and the GLP-1 receptor (GLP1R) has been identified in the lung, kidney, blood vessels and sinoatrial cells of the heart (Richards et al. 2013; Pyke et al. 2014).”
BackgroundAviles Bueno, B., Soler, M. J., Perez-Belmonte, L., Jimenez Millan, A., Rivas Ruiz, F., & Garcia de Lucas, M. D. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac096 · Cited by 43
“Experimental data demonstrated that the improvements in renal outcomes may be ascribed in part to the antiinflammatory antioxidative and hemodynamic properties of the GLP1-RAs [32].”
BackgroundThe endogenous preproglucagon system is not essential for gut growth homeostasis in mice
Wismann, P., Barkholt, P., Secher, T., Vrang, N., Hansen, H. B., Jeppesen, P. B., Baggio, L. L., Koehler, J. A., Drucker, D. J., Sandoval, D. A., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.007 · Cited by 43
“Glp1r was also localized to nerve plexuses of the submucosa and muscularis along the full rostro-caudal extension of the intestinal tract [17,39,58].”
BackgroundSafety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)
Rehani, P. R., Iftikhar, H., Nakajima, M., Tanaka, T., Jabbar, Z., & Rehani, R. (2019) · Journal of Diabetes Research · doi:10.1155/2019/4267357 · Cited by 55
“However, liraglutide, in specific instances, has been shown to reduce adverse cardiovascular events [25, 27, 28].”
BackgroundThe Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Yin, W. L., Bain, S. C., & Min, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00798-x · Cited by 45
Wei, J., Wang, R., Ye, H., Wang, Y., Wang, L., & Zhang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.910256 · Cited by 43
Wu, S., Lu, W., Chen, Z., Dai, Y., Chen, K., & Zhang, S. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00970-2 · Cited by 50
“Since the distributions of GLP-1R in sino-atrial node and ventricular cardiomyocytes [31, 38], a previous study indicated that the direct activations of BMI body mass index, CVOT cardiovascular outcome trial”
BackgroundSmits, M. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Diamant, M., van Raalte, D. H., & Serné, E. H. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305447 · Cited by 44
“A direct effect is conceivable, and can be explained by the observation that the GLP-1 receptor is present on smooth muscle cells of human arteries.(14) Alternatively, exenatide could interact with factors known to alter precapillary arteriolar tone, an indirect effect.”
BackgroundAn overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
“G-protein-coupled receptor expressed on pancreatic islet α- and β-cells and many other tissues including lung, heart, blood vessels, gastrointestinal tract, kidney, and the peripheral and CNS.[38,39] In the pancreatic β-”
BackgroundNauck, M. A., Kahle, M., Baranov, O., Deacon, C. F., & Holst, J. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12802 · Cited by 44
“quential improvements in glucose control can only partially be inhibited by the GLP-1 receptor agonist exendin [9-39].”
BackgroundMethodInfluentialOkabe, K., Matsushima, S., Ikeda, S., Ikeda, M., Ishikita, A., Tadokoro, T., Enzan, N., Yamamoto, T., Sada, M., Deguchi, H., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14400 · Cited by 46
“GLP-1 receptor is known to be expressed in various types of cells, including smooth muscle cells, β-cells, and parietal cells.(37) However, its expression in cardiomyocytes is controversial.”
BackgroundQi, L., Gröger, M., Sharma, A., Goswami, I., Chen, E., Zhong, F., Ram, A., Healy, K. E., Hsiao, E. C., Willenbring, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52258-w · Cited by 54
“In accordance, we found little GLP1R gene expression in iHEPs and primary human hepatocytes, which con fi rms previous fi ndings made in whole liver 62,63 .”
BackgroundLiraglutide: A Review of Its Use in the Management of Obesity
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-015-0408-8 · Cited by 48
“out the body, including in the pancreas, stomach, intestine, lung, kidney, heart, peripheral nervous system and CNS [19].”
BackgroundInfluentialPatoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Enteroendocrine Regulation of Nutrient Absorption
McCauley, H. A. (2019) · Journal of Nutrition · doi:10.1093/jn/nxz191 · Cited by 50
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 41
“receptor expression in the pancreas, brain, kidney, lung, heart and stomach (Pyke et al., 2014).”
BackgroundInfluentialDecara, J., Arrabal, S., Beiroa, D., Rivera, P., Vargas, A., Serrano, A., Pavón, F. J., Ballesteros, J., Dieguez, C., Nogueiras, R., et al. (2016) · BioFactors · doi:10.1002/biof.1295 · Cited by 42
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
Bomholt, A. B., Johansen, C. D., Christensen, J. B., Kjeldsen, S. A. S., Galsgaard, K. D., Winther-Sørensen, M., Serizawa, R., Hornum, M., Porrini, E., Pedersen, J., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04242-7 · Cited by 42
Self-citationPharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 55
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 44
Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41
Lipš, M., Mráz, M., Kloučková, J., Kopecký, P., Dobiáš, M., Křížová, J., Lindner, J., Diamant, M., & Haluzík, M. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13029 · Cited by 39
“to the former suggestion that it was abundantly expressed on cardiomyocytes.(10) By contrast, the reduction in E/E’ ratio might suggest a positive effect of exenatide on LV diastolic function that, considering”
BackgroundMaiseyeu, A., Di, L., Ravodina, A. M., Barajas‐Espinosa, A. R., Sakamoto, A., Chaplin, A. M. L., Zhong, J., Gao, H., Mignery, M., Narula, N., et al. (2022) · Theranostics · doi:10.7150/thno.66456 · Cited by 44
“To understand the relevance of these findings in human atherosclerosis, a library of human atherosclerotic plaques with varying stages of atherosclerosis was screened for their immuno reactivity to extensively validated 3F52 anti-GLP-1R monoclonal antibody [15].”
BackgroundAsmar, A., Simonsen, L., Asmar, M., Madsbad, S., Holst, J. J., Frandsen, E., Moro, C., Sorensen, C. M., Jonassen, T., & Bülow, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00518.2015 · Cited by 41
Wewer Albrechtsen, N. J., Albrechtsen, R., Bremholm, L., Svendsen, B., Kuhre, R. E., Poulsen, S. S., Christiansen, C. B., Jensen, E. P., Janus, C., Hilsted, L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.051 · Cited by 40
“Using a well-characterized and validated GLP-1 receptor (GLP-1R) antibody (Pyke et al., 2014), we demonstrated GLP-1R expression in pancreatic acinar cells (positive staining for amylase), which was missing in tissue biopsy specimens from GLP-1R knockout mice (Figure 1C).”
BackgroundGlucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
Asmar, A., Asmar, M., Simonsen, L., Madsbad, S., Holst, J. J., Hartmann, B., Sorensen, C. M., & Bülow, J. (2017) · Physiological Reports · doi:10.14814/phy2.13073 · Cited by 41
“In healthy individuals (Asmar et al. 2015) and patients with type 2 diabetes (Asmar et al. 2016a), we demonstrated a GLP-1-induced increase in heart rate, possibly due to direct effects of GLP-1 on the heart (Pyke et al. 2014).”
BackgroundMethodNovel therapies for diabetic kidney disease
Cherney, D. Z. I., & Bakris, G. L. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.005 · Cited by 48
Love, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13045 · Cited by 40
“In addition, GLP-1 receptors are expressed infrequently in the ventricular myocytes but abundantly in vascular endothelial cells and smooth muscle cells, suggesting a vasculature-related cardiac effect.(86,87)”
BackgroundThe interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Reagents and models for detecting endogenous GLP1R and GIPR
Ast, J., Broichhagen, J., & Hodson, D. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103739 · Cited by 40
Greco, C., Santi, D., Brigante, G., Pacchioni, C., & Simoni, M. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0314 · Cited by 43
“However, the identification of GLP-1R expression in mouse atria [36] and in monkey sinoatrial node [37] raised the additional possibility that GLP-1 may directly modulate HR through the cardiac GLP-1R.”
The role of gut hormones in appetite regulation (review)
Maric, G. D., Gazibara, T. M., Zaletel, I. V., Labudović‐Borović, M., Tomanović, N., Ćirić, M., & Puškaš, N. (2014) · Acta Physiologica Hungarica · doi:10.1556/aphysiol.101.2014.4.1 · Cited by 59
GLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 42
“macrophages and monocytes [9, 21].”
BackgroundInfluentialRonn, J., Jensen, E. P., Wewer Albrechtsen, N. J., Holst, J. J., & Sorensen, C. M. (2017) · Physiological Reports · doi:10.14814/phy2.13503 · Cited by 40
“2011), whereas others show that it is only expressed in the renal vasculature (Fujita et al. 2013; Pyke et al. 2014; Jensen et al. 2015).”
BackgroundDodd, R. B., Wilkinson, T. C. I., & Schofield, D. J. (2018) · BioDrugs · doi:10.1007/s40259-018-0289-y · Cited by 44
“Purified extracellular domains have been used to obtain antibodies against several GPCRs, including PAR4 [25] (class A), GPR56 [26], CGRP-R [27] and GLP1-R [28], which are all class B receptors.”
MethodGLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
“Through careful and rigorous testing, four antibodies are now confirmed to specifically target human/primate/rat/mouse/dog GLP1R, as tested using gold-standard validation such as Glp1r -/- tissue, or cells transfected with GLP1R vs. mock plasmid [23 – 28] (reviewed in [29]).”
Ren, H., Li, J. J., Zhang, N., Hu, L. A., Ma, Y., Tagari, P. C., Xu, J., & Zhang, M.-Y. (2020) · Communications Biology · doi:10.1038/s42003-020-0867-7 · Cited by 41
Liraglutide pretreatment attenuates sepsis-induced acute lung injury
Baer, B., Putz, N. D., Riedmann, K. J., Gonski, S. K., Lin, J., Ware, L. B., Toki, S., Peebles, R. S., Cahill, K. N., & Bastarache, J. A. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00041.2023 · Cited by 46
Shen, R., Qin, S., Lv, Y., Liu, D., Ke, Q., Shi, C., Jiang, L., Yang, J., & Zhou, Y. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167060 · Cited by 45
Transmission of Major Arboviruses in Brazil: The Role of Aedes aegypti and Aedes albopictus Vectors
Chouin-Carneiro, T., & dos Santos, F. B. (2017) · InTech eBooks · doi:10.5772/66946 · Cited by 53
Case Reports of Pre-clinical Replication Studies in Metabolism and Diabetes
von Herrath, M., Pagni, P. P., Grove, K., Christoffersson, G., Tang-Christensen, M., Karlsen, A. E., & Petersen, J. S. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.004 · Cited by 39
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“In the gastrointestinal tract, protein expression of the GLP-1R was only detected in the HCL-secreting parietal cells and the smooth muscle cells of the stomach, the Brunner's gland of the duodenum, cells of the nervous plexus [132] and intestinal intraepithelial lymphocytes [133], but not on chylomicron forming enter…”
BackgroundTreatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
“[124] At present, the potential adverse effect of the increased heart rate is unknown.”
BackgroundEffect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
Frøssing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Endocrine Connections · doi:10.1530/ec-17-0327 · Cited by 38
Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
Yang, F., Luo, X., Li, J., Yu, L., Zeng, F., Huang, X., Lan, Y., & Liu, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113236 · Cited by 44
Lee, B. S., Holstein‐Rathlou, N., Sosnovtseva, O. V., & Sørensen, C. M. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00147.2023 · Cited by 42
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
Li, W., Alazawi, W., & Loomba, R. S. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00260-2 · Cited by 57
Li, N., Zhao, Y., Yue, Y., Chen, L., Yao, Z., & Niu, W. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.095 · Cited by 40
Ke, J., Liu, Y., Yang, J., Lu, R., Tian, Q., Hou, W., Wang, G., Wei, R., & Hong, T. (2017) · Scientific Reports · doi:10.1038/srep41085 · Cited by 38
“Recently, Pyke and colleagues 39 created a mouse anti-GLP-1R monoclonal antibody, which is highly sensitive and specific in the detection of GLP-1R in primate tissues.”
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Dieter, B. P., Alicic, R. Z., & Tuttle, K. R. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00211.2018 · Cited by 38
Shigeoka, T., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Horikawa, T., Tanaka, T., Irie, S., Motonaga, R., Hamanoue, N., Tanabe, M., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13247 · Cited by 39
Ayoub, M., Faris, C., Juranovic, T., Chela, H. K., & Daglilar, E. S. (2024) · Cancers · doi:10.3390/cancers16091625 · Cited by 41
“Studies on rodents showed that the stimulation of GLP-1 receptors on thyroid parafolicular C cells stimulates cAMP-dependent synthesis and secretion of calcitonin and, upon longer-term exposure, causes the proliferation of C cells and the formation of C-cell adenomas and carcinomas [76,77].”
BackgroundCardiovascular safety and benefits of GLP-1 receptor agonists
Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1281246 · Cited by 34
Development and characterisation of a novel glucagon like peptide-1 receptor antibody
Biggs, E. K., Liang, L., Naylor, J., Madalli, S., Collier, R., Coghlan, M. P., Baker, D. J., Hornigold, D. C., Ravn, P., Reimann, F., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4491-0 · Cited by 37
“Aside from this, the monoclonal antibody mAb3F52 with specificity for human and monkey GLP1R has been generated and used in immunostaining [5].”
BackgroundMethodMills, E. P., Brown, K. P. D., Smith, J. D., Vang, P. W., & Trotta, K. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817741852 · Cited by 41
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 42
Zhou, W., Shao, W., Zhang, Y., Liu, D., Liu, M., & Jin, T. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00292.2020 · Cited by 36
Zhai, S., Liu, C., Vimalraj, S., Subramanian, R., Abullais, S. S., Arora, S., & Sekaran, S. (2023) · Peptides · doi:10.1016/j.peptides.2023.170974 · Cited by 39
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 44
Hansen, H. H., Pors, S. E., Andersen, M. W., Vyberg, M., Nøhr-Meldgaard, J., Nielsen, M. H., Oró, D., Madsen, M. R., Lewińska, M., Møllerhøj, M. B., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-50328-5 · Cited by 42
Sasaki, S., Miyatsuka, T., Matsuoka, T., Takahara, M., Yamamoto, Y., Yasuda, T., Kaneto, H., Fujitani, Y., German, M. S., Akiyama, H., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3728-z · Cited by 37
“Generation of transgenic mice that overexpress GLP-1 receptor Since the expression of GLP1R is restricted to only a proportion of exocrine cells at much lower levels than that in beta cells [23], andGlp1r is expressed in pancreatic endocrine progenitors (Fig.”
Background111In-exendin Uptake in the Pancreas Correlates With the β-Cell Mass and Not With the α-Cell Mass
Brom, M., Joosten, L., Frielink, C., Boerman, O. C., & Gotthardt, M. (2014) · Diabetes · doi:10.2337/db14-1212 · Cited by 43
“Although relevant GLP-1 receptor (GLP-1R) expression in the exocrine pancreas was claimed (4–6), recent studies showed only low expression in acinar cells and no expression in ductal cells, whereas high GLP-1R expression could be demonstrated in the pancreatic islets, as determined by in vitro autoradiography with (12…”
BackgroundBeger, H. G., Mayer, B., & Poch, B. (2020) · HPB · doi:10.1016/j.hpb.2019.12.016 · Cited by 37
Dalbøge, L. S., Christensen, M. S., Madsen, M. R., Secher, T., Endlich, N., Drenić, V., Manresa-Arraut, A., Hansen, H. H., Rune, I., Fink, L. N., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071661 · Cited by 43
“In support of intrarenal hemodynamic effects of GLP-1R agonists, localization of GLP-1Rs in the kidney is reported to be restricted to vascular smooth muscle cells [47,48,50], and GLP-1R activation is suggested to mediate renal vasorelaxant and blood flow stimulation to preserve glomerular function [47,48,51].”
BackgroundHansen, M. S., Tencerová, M., Frølich, J. S., Kassem, M. S., & Frost, M. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12850 · Cited by 39
Sélley, E., Kun, S., Szijártó, I., Kertész, M., Wittmann, I., & Molnár, G. (2016) · Hormone and Metabolic Research · doi:10.1055/s-0042-101794 · Cited by 35
“Although the presence of glucagon receptors on hepatocytes is well known, their density is increased following exercise in fasting in rats [29], and the presence of GLP-1 receptors on hepatocytes is not so evident [1, 30].”
Pais, R., Rievaj, J., Meek, C. L., Costa, G. D., Jayamaha, S., Alexander, R. T., Reimann, F., & Gribble, F. M. (2016) · The Journal of Physiology · doi:10.1113/jp272053 · Cited by 37
“…homeostasis, the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes has revealed their effects on heart rate and blood pressure, probably reflecting the expression of GLP1R in the heart, brainstem, kidney and arterial vasculature (Pyke et al. 2014; Richards et al. 2014).”
BackgroundGLP‐1 Is a Coronary Artery Vasodilator in Humans
Clarke, S. J., Giblett, J. P., Yang, L., Hubsch, A., Zhao, T. X., Aetesam‐ur‐Rahman, M., West, N. E. J., O'Sullivan, M., Figg, N. L., Bennett, M. R., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.010321 · Cited by 40
“Studies assessing the incretin hormone GLP-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (the enzyme responsible for GLP-1 [7-36] breakdown to metabolically inactive GLP-1 [9–36]) inhibitors, used to treat diabetes From the Division of Cardiovascular Medicine (S.”
Method
Metadata
- Authors
- Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Department of Diabetes Structural Biology (S.R.-R.), Novo Nordisk, 2880 Bagsværd, Denmark
- Rigshospitalet (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 1280-1290
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1979288606
- Cited by
- 876
- References
- 37
- Citations by year
- 2026: 99 · 2025: 91 · 2024: 103 · 2023: 56 · 2022: 70 · 2021: 64 · 2020: 64 · 2019: 57 · 2018: 60 · 2017: 64 · 2016: 61 · 2015: 58 · 2014: 27
- FWCI
- 56.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, receptor localization, type 2 diabetes, GLP-1 analogues, pancreatic beta cells, sinoatrial node, Brunner's glands, myenteric neurons, smooth muscle cells, kidney, heart, gastrointestinal tract, receptor expression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Insulin Secretion, Animals, Haplorhini, Antibodies, Monoclonal, Blood Pressure, Body Weight, Cell Line, Duodenum, Glucagon, Cricetinae, Heart Rate, Humans, Insulin, Ligands, Mice, Inbred C57BL, Peptides, Protein Binding, Tissue Distribution, Transfection, Venoms, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.